- freely available
Exploring the Glycosylation of Serum CA125
AbstractOvarian cancer is the most lethal gynaecologic cancer affecting women. The most widely used biomarker for ovarian cancer, CA125, lacks sensitivity and specificity. Here, we explored differences in glycosylation of CA125 between serum from patients with ovarian cancer and healthy controls. We found differences between CA125 N-glycans from patient sera compared to controls. These include increases in core-fucosylated bi-antennary monosialylated glycans, as well as decreases in mostly bisecting bi-antennary and non-fucosylated glycans in patients compared to controls. Measurement of the glycosylated state of CA125 may therefore provide a more specific biomarker for patients with ovarian cancer.
Share & Cite This Article
Saldova, R.; Struwe, W.B.; Wynne, K.; Elia, G.; Duffy, M.J.; Rudd, P.M. Exploring the Glycosylation of Serum CA125. Int. J. Mol. Sci. 2013, 14, 15636-15654.View more citation formats
Saldova R, Struwe WB, Wynne K, Elia G, Duffy MJ, Rudd PM. Exploring the Glycosylation of Serum CA125. International Journal of Molecular Sciences. 2013; 14(8):15636-15654.Chicago/Turabian Style
Saldova, Radka; Struwe, Weston B.; Wynne, Kieran; Elia, Giuliano; Duffy, Michael J.; Rudd, Pauline M. 2013. "Exploring the Glycosylation of Serum CA125." Int. J. Mol. Sci. 14, no. 8: 15636-15654.